text: <unk>  is a P2Y12 platelet inhibitor that is FDA approved for the prevention of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor and undergoing percutaneous coronary intervention (PCI).   Common adverse reactions include bleeding.
option_0: Cangrelor
option_1: Iofendylate
option_2: Cetrorelix
option_3: Riociguat
option_4: Temocapril
option_5: Bemiparin
option_6: Prasugrel
option_7: Guanadrel